<code id='DE6276D2B6'></code><style id='DE6276D2B6'></style>
    • <acronym id='DE6276D2B6'></acronym>
      <center id='DE6276D2B6'><center id='DE6276D2B6'><tfoot id='DE6276D2B6'></tfoot></center><abbr id='DE6276D2B6'><dir id='DE6276D2B6'><tfoot id='DE6276D2B6'></tfoot><noframes id='DE6276D2B6'>

    • <optgroup id='DE6276D2B6'><strike id='DE6276D2B6'><sup id='DE6276D2B6'></sup></strike><code id='DE6276D2B6'></code></optgroup>
        1. <b id='DE6276D2B6'><label id='DE6276D2B6'><select id='DE6276D2B6'><dt id='DE6276D2B6'><span id='DE6276D2B6'></span></dt></select></label></b><u id='DE6276D2B6'></u>
          <i id='DE6276D2B6'><strike id='DE6276D2B6'><tt id='DE6276D2B6'><pre id='DE6276D2B6'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:773
          Mark Lennihan/AP

          Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

          The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

          advertisement

          Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          The untold story of TV’s first prescription drug ad
          The untold story of TV’s first prescription drug ad

          CourtesyLizMoenchLiz Moenchthoughtitwasobvious.DuringherjobinterviewwithBootsPharmaceuticalsin1981,a

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          Charges dismissed against white woman who spat on Black woman during protests in Connecticut

          HARTFORD,Conn.--HARTFORD,Conn.(AP)—AjudgeFridaydismissedhatecrimeandotherchargesagainstawhitewomanwh